Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Johnson & Johnson
Headquarters: New Brunswick, NJ, United States of America
Website: http://www.jnj.com
Year Founded: 1887
Status: Public
Industry Sector: HealthTechnology
CEO: Joaquin Duato, MBA
Number Of Employees: 138,100
Enterprise Value: $364,651,828,000
PE Ratio: 26.63
Exchange/Ticker 1: NYSE:JNJ
Exchange/Ticker 2: N/A
Latest Market Cap: $371,984,433,152
BioCentury | Apr 16, 2025
Management Tracks
In wake of Anthos buyout, CFO McIntyre joins Inhibikase
BioCentury’s Management Roundup also includes updates from Galapagos, Proqr, GC, Gates MRI, Viatris and AB Sciex
BioCentury | Apr 15, 2025
Politics, Policy & Law
Drug companies’ playbook for deflecting tariffs
To avoid sweeping tariffs, pharmas announce U.S. manufacturing investments, warn of generics shortages
BioCentury | Apr 15, 2025
Deals
Slow season for biopharma M&A amid stormy markets: Deals Report
Uncertainty in markets may be quashing appetite to complete transactions
BioCentury | Apr 11, 2025
Management Tracks
Preminger leaving J&J Innovation
Plus: Management changes at Kymera, Arcutis and Merakris
BioCentury | Apr 10, 2025
Management Tracks
New CEOs at Alterome, Valo and Imbria
Plus: Updates from Harbour BioMed, Ottimo and NeOnc
BioCentury | Apr 9, 2025
Management Tracks
As Rocket awaits FDA review, J&J vet Chaudhuri joins as commercial lead
Plus: C-suite changes at Freenome, Telix, Trex Bio, Myricx, General Oncology, Bostongene and Acrivon
BioCentury | Apr 8, 2025
Product Development
VEGF multispecifics get innovative at AACR 2025
New binding domains, target combinations and molecule structures define the VEGF multispecifics to be presented at AACR 2025
BioCentury | Apr 5, 2025
Discovery & Translation
Science Spotlight: A FOXP3 regulator to enhance induced Tregs
BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more
BioCentury | Apr 2, 2025
Product Development
VEGF bispecifics make inroads in other cancers, and more: Clinical Report
Plus: The week’s gainers and decliners after data
BioCentury | Apr 1, 2025
Politics, Policy & Law
FDA layoffs could cripple agency, former FDA commissioners say
Reviews of novel drugs could be disrupted, long-term plans for FDA unclear
Items per page:
1 - 10 of 11119